Data Under Review
Some valuation figures for this stock are being recalibrated. Hidden fields will return after data review.
Reported as ticker: KREBSBIO· We're continuously improving data quality. Contact support if this persists.
KREBS BIOCHEMICALS & IND
KREBSBIO · General/Diversified · NSE
₹56
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for KREBSBIO yet. Reason: Data Limited.
Updated 20h ago
YieldIQ Score
—
Piotroski F-Score
4/9
Economic Moat
None
Confidence
0%
ROE
10.4%
Debt/Equity
—
WACC
11.1%
Market Cap
₹120.46 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
-5.5%
Return on capital employed
EV / EBITDA
—
Enterprise multiple
Debt / EBITDA
—
Leverage vs earnings
Interest Coverage
-3.6×
EBIT covers interest
Current Ratio
0.10×
Short-term liquidity
Asset Turnover
0.14×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-23.1%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
Ratio Trends
KREBSBIO · last 9 annual periods
ROE
10.4%
ROCE
-5.5%
Operating Margin
—
Debt / Equity
—
PE
—
EV / EBITDA
—
Historical Financials
KREBSBIO · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹59.7 Cr | ₹52.1 Cr | ₹50.4 Cr | ₹43.3 Cr | ₹23.7 Cr | -20.6% |
| EBITDA | ₹-32.8 Cr | ₹-15.2 Cr | ₹-8.3 Cr | ₹-14.3 Cr | ₹-3.4 Cr | — |
| EBIT | ₹-39.1 Cr | ₹-21.7 Cr | ₹-15.0 Cr | — | — | — |
| PAT | ₹-44.5 Cr | ₹-24.7 Cr | ₹-19.7 Cr | ₹-26.9 Cr | ₹-16.9 Cr | — |
| EPS (diluted) | ₹-20.81 | ₹-11.30 | ₹-9.16 | — | — | — |
| CFO | ₹-17.2 Cr | ₹-24.7 Cr | ₹2.4 Cr | ₹-7.9 Cr | ₹-1.9 Cr | — |
| CapEx | ₹-23.5 Cr | ₹-10.9 Cr | ₹-9.4 Cr | ₹-3.6 Cr | ₹-3.2 Cr | — |
| FCF | ₹-40.7 Cr | ₹-35.6 Cr | ₹-7.1 Cr | ₹-11.5 Cr | ₹-5.1 Cr | — |
| Total Assets | ₹190 Cr | ₹175 Cr | ₹178 Cr | ₹169 Cr | ₹163 Cr | -3.7% |
| Total Debt | ₹188 Cr | ₹228 Cr | ₹239 Cr | ₹257 Cr | ₹225 Cr | +4.6% |
| Shareholders' Equity | ₹-75.1 Cr | ₹-99.5 Cr | ₹-119 Cr | ₹-146 Cr | ₹-163 Cr | — |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
KREBSBIO vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
ALPA ALPA LABORATORIES LTD | -7.6% | 17 | Near Fair Value | 11.4% | — |
BALPHARMA BALPHARMA | — | — | Pending | 9.3% | — |
PAR PAR | — | — | Pending | 13.5% | — |
NATCAPSUQ NATCAPSUQ | — | — | Pending | 0.3% | — |
VAISHALI VAISHALI | — | — | Pending | 1.3% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for KREBSBIO in the last 10 years.
Risk Analysis
Volatility & drawdown
Risk profile of KREBSBIO →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for KREBSBIO →
Compare
Head-to-head with peers
Compare KREBSBIO side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse KREBSBIONow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.